Sugi Predict

Sugi Predict / Compounds / SCHEMBL844675

SCHEMBL844675

SCHEMBL844675

CCOC(=O)C(Br)C(=O)CC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SOAT1 P35610 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.42
▸ TRPA1 O75762 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ ALOX15 P16050 1/20 0.39
▸ MGAM O43451 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ SI P14410 1/20 0.39
▸ MGAM2 Q2M2H8 1/20 0.39
▸ PIN1 Q13526 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30037172 0.85 GAA (0.47) SOAT1ALDH1A1TRPA1LMNAHSD17B10
SCHEMBL166529 0.85 ALDH1A1 (0.50) SOAT1ALDH1A1TRPA1LMNAHSD17B10
SCHEMBL6297049 0.84 ALDH1A1 (0.50) SOAT1ALDH1A1TRPA1LMNAHSD17B10
Propane SCHEMBL6048777 0.82 ALDH1A1 (0.48) SOAT1ALDH1A1TRPA1LMNAHSD17B10
SCHEMBL14888952 0.82 ALDH1A1 (0.39) SOAT1ALDH1A1TRPA1LMNAHSD17B10
SCHEMBL4406553 0.81 ZDHHC7 (0.44) SOAT1ALDH1A1TRPA1MGAMGAA
SCHEMBL22642270 0.80 ALDH1A1 (0.37) SOAT1ALDH1A1TRPA1LMNAHSD17B10
SCHEMBL2552735 0.80 GAA (0.56) SOAT1ALDH1A1TRPA1LMNAHSD17B10
Isobutane SCHEMBL6048714 0.80 ALDH1A1 (0.46) SOAT1ALDH1A1TRPA1LMNAHSD17B10
Butane SCHEMBL6048693 0.80 ALDH1A1 (0.46) SOAT1ALDH1A1TRPA1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120077048-A Tricyclic compounds and uses thereof 诺华股份有限公司 2025-05-30 — — CN disclosed
WO-2024255765-A1 NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) 2024-12-19 — — WO disclosed
US-20240360118-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-10-31 — — US disclosed
WO-2024220887-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINONE WRN INHIBITORS NIMBUS WADJET, INC. (US) 2024-10-24 — — WO disclosed
US-20240245694-A1 Tricyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-07-25 — — US disclosed
WO-2024153155-A1 DOUBLE-HETEROCYCLIC WRN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 成都微芯药业有限公司 2024-07-25 — — WO disclosed
WO-2024079623-A1 TRICYCLIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2024-04-18 — — WO disclosed
EP-4347596-A1 TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) Novartis AG (CH) 2024-04-10 — — EP disclosed
US-11878973-B2 Bicyclic compounds and their uses NOVARTIS AG (CH) 2024-01-23 — — US disclosed
CN-117425657-A Triazolo-pyrimidine analogs for the treatment of diseases associated with inhibition of Wonna syndrome RECzochralski enzyme (WRN) 诺华股份有限公司 2024-01-19 — — CN disclosed
US-20140155387-A1 Anti-Inflammation Compounds QURIENT, CO. LTD. (KR) 2014-06-05 — — US disclosed
US-20130065884-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2013-03-14 — — US disclosed
US-20130065884-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2013-03-14 — — US disclosed
WO-2012143796-A2 ANTI-INFLAMMATION COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2012-10-26 — — WO disclosed
EP-2432776-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS Chlorion Pharma, Inc. (CA) 2012-03-28 — — EP disclosed
WO-2011113606-A1 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2011-09-22 — — WO disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 — — US disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 — — US disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 — — US disclosed
WO-2010132999-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS CHLORION PHARMA, INC. (CA) 2010-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP SOAT1 4729/4885ALDH1A1 577/4885TRPA1 196/4885
US-20240360118-A1 Bicyclic Compounds and their Uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 SOAT1 2170/4885ALDH1A1 2542/4885TRPA1 2520/4885
US-11878973-B2 Bicyclic compounds and their uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 SOAT1 2170/4885ALDH1A1 2542/4885TRPA1 2520/4885
US-20240245694-A1 Tricyclic Compounds and their Uses F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R SOAT1 2429/4885ALDH1A1 2299/4885TRPA1 1711/4885
US-20130065884-A1 Anti-Infective Compounds RABGGTB, ELANE, SERPINB1 SOAT1 1031/4885ALDH1A1 3932/4885TRPA1 2287/4885
US-20140155387-A1 Anti-Inflammation Compounds NR0B1, NR0B2, NR5A2 SOAT1 787/4885ALDH1A1 3926/4885TRPA1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.